絞り込み

16548

広告

宇宙旅行あと一歩 米ベンチャーが有人実験成功 (毎日新聞)

[PR] 【ワシントン中井正裕】英ヴァージン・グループ傘下の宇宙開発ベンチャー、ヴァージン・ギャラクティック社は13日、カリフォルニア州で宇宙船「スペースシップ...

  1. [企業] Merck &...
  2. 本庶さんノーベル授賞式から帰国 「貴重な...
  3. [企業] 持効インスリンLantusの製...
  4. 調達情報 平成31年度労働保険料等に係る...

ニュース一覧

Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study.

著者 Klok FA , Barco S , Turpie AGG , Haas S , Kreutz R , Mantovani LG , Gebel M , Herpers M , Bugge JP , Kostantinides SV , Ageno W
Br J Haematol.2018 Aug 19 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (36view , 0users)

Full Text Sources

Venous thromboembolism (VTE)-BLEED, a decision tool for predicting major bleeding during chronic anticoagulation for VTE has not yet been validated in practice-based conditions. We calculated the prognostic indices of VTE-BLEED for major bleeding after day 30 and day 90, as well as for recurrent VTE and all-cause mortality, in 4457 patients enrolled in the international, prospective XALIA study. The median at-risk time was 190 days (interquartile range 106-360). The crude hazard ratio (HR) for major bleeding after day 30 was 2·6 [95% confidence interval (CI) 1·3-5·2] and the treatment-adjusted HR was 2·3 (95% CI 1·1-4·5) for VTE-BLEED high (versus low) risk patients: the corresponding values for major bleeding after day 90 were 3·8 (95% CI 1·6-9·3) and 3·2 (95% CI 1·3-7·7), respectively. The predictive value of VTE-BLEED was similar in selected patients with unprovoked VTE or those treated with rivaroxaban. High VTE-BLEED score was associated with higher incidence of all-cause mortality (treatment-adjusted HR 11, 95% CI 4·8-23), but not evidently with recurrent VTE (treatment-adjusted HR 1·5; 95% CI 0·85-2·7). These results confirm the predictive value of VTE-BLEED in practice-based data in patients treated with rivaroxaban or conventional anticoagulation, supporting the hypothesis that VTE-BLEED may be useful for making management decisions on the duration of anticoagulant therapy.
PMID: 30123981 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード